# SGCG

## Overview
The SGCG gene encodes the gamma-sarcoglycan protein, a critical component of the sarcoglycan complex within the dystrophin-associated glycoprotein complex (DGC) in muscle tissues. Gamma-sarcoglycan is a type II transmembrane glycoprotein that plays a pivotal role in maintaining the structural integrity of muscle cell membranes by linking the cytoskeleton to the extracellular matrix. This linkage is essential for protecting muscle fibers from contraction-induced damage, thereby preserving muscle function. Mutations in the SGCG gene can lead to sarcoglycanopathies, a subset of limb-girdle muscular dystrophies, characterized by progressive muscle weakness and wasting. The study of SGCG and its interactions with other proteins provides valuable insights into muscle physiology and the pathogenesis of muscular dystrophies (Smith2022Novel; Israeli2019An).

## Structure
The SGCG gene encodes the γ-sarcoglycan protein, a component of the sarcoglycan complex within the dystrophin-associated glycoprotein complex (DGC), which is crucial for muscle integrity. γ-Sarcoglycan is a type II transmembrane protein characterized by a short intracellular domain, a single transmembrane pass, and a larger extracellular domain. The extracellular domain is notable for containing N-glycosylation sites, which are common post-translational modifications that can affect protein stability and function (Israeli2019An; Gao2015Reengineering).

The primary structure of γ-sarcoglycan includes a 37 amino acid intracellular domain, a 21 amino acid transmembrane domain, and a 233 amino acid extracellular domain (Gao2015Reengineering). The protein's tertiary structure involves its integration into the sarcoglycan complex, where it forms a heterotetramer with α-, β-, and δ-sarcoglycans, contributing to the quaternary structure of the complex (Smith2022Novel).

The γ-sarcoglycan protein also contains a cysteine-rich domain, which is important for membrane targeting and function (Gao2015Reengineering). This domain is essential for the protein's role in maintaining muscle cell membrane integrity and its involvement in signaling pathways (Smith2022Novel).

## Function
The SGCG gene encodes gamma-sarcoglycan, a transmembrane glycoprotein that is a crucial component of the sarcoglycan complex within the dystrophin-associated glycoprotein complex (DGC) in striated muscles. This complex plays a vital role in maintaining the structural stability of muscle cell membranes by linking the subsarcolemmal cytoskeleton to the extracellular matrix. This linkage is essential for protecting muscle fibers from contraction-induced damage, thereby preserving muscle integrity and function (Israeli2019An; Henriques2018Different).

In healthy human cells, gamma-sarcoglycan is primarily active in the sarcolemma of skeletal and cardiac muscle cells. It contributes to the stability and integrity of the muscle cell membrane during contraction, which is crucial for normal muscle function (Israeli2019An). The sarcoglycan complex, including gamma-sarcoglycan, is involved in force transduction and membrane stabilization, ensuring that muscle fibers can withstand mechanical stress without damage (Boulay2015The).

Mutations in the SGCG gene can disrupt the sarcoglycan complex, leading to sarcoglycanopathies, a group of limb girdle muscular dystrophies characterized by muscle fiber damage and progressive muscle wasting (Israeli2019An).

## Clinical Significance
Mutations in the SGCG gene are associated with limb-girdle muscular dystrophy type 2C (LGMD2C), a form of sarcoglycanopathy characterized by progressive muscle weakness and wasting, particularly affecting the limb-girdle region. These mutations disrupt the sarcoglycan complex, which is crucial for maintaining muscle fiber stability (Trabelsi2008Revised; White2005Sarcoglycanopathies). The clinical presentation of LGMD2C can vary significantly, with symptoms often appearing in childhood and leading to severe disability, including loss of ambulation before the age of 18 (AlonsoPérez2020New).

Specific mutations in the SGCG gene, such as c.525delT and c.848G>A, have been identified as common in certain populations and are linked to severe clinical phenotypes (Trabelsi2008Revised; AlonsoPérez2020New). The c.787G>A mutation, prevalent among Puerto Rican Hispanics, results in a milder disease progression compared to other mutations (Al‐Zaidy2015A). Alterations in protein expression levels due to these mutations can influence disease severity, with lower residual expression correlating with more rapid disease progression (AlonsoPérez2020New).

The SGCG gene's mutations can also lead to secondary deficiencies in other sarcoglycan proteins, further complicating the clinical picture and suggesting the involvement of additional genetic factors (Trabelsi2008Revised).

## Interactions
The γ-sarcoglycan (SGCG) protein is a component of the sarcoglycan complex, which is part of the larger dystrophin-glycoprotein complex (DGC) in muscle cells. SGCG interacts with other sarcoglycans, including α-, β-, and δ-sarcoglycans, to form a stable complex that links the cytoskeleton to the extracellular matrix, playing a crucial role in maintaining muscle integrity and function (Smith2022Novel).

SGCG has been shown to interact with the Na+-K+-Cl- cotransporter NKCC1, which co-localizes with SGCG in muscle membranes. This interaction is involved in signaling pathways, particularly those affecting ERK1/2 phosphorylation, which are important for muscle function and response to mechanical stress (Smith2022Novel). The interaction between SGCG and NKCC1 is characterized as low-avidity, suggesting it may be transient or condition-dependent (Smith2022Novel).

Additionally, SGCG interacts with archvillin, a membrane-cytoskeleton linker protein involved in ERK1/2 signaling. This interaction is significant for ERK regulation and survival signaling in muscle tissues (Smith2022Novel). The study of these interactions provides insights into the role of SGCG in muscle physiology and its potential involvement in muscular dystrophies.


## References


[1. (Trabelsi2008Revised) Madiha Trabelsi, Niloufar Kavian, Fatma Daoud, Virginie Commere, Nathalie Deburgrave, Caroline Beugnet, Stephane Llense, Jean Claude Barbot, Aurélie Vasson, Jean Claude Kaplan, France Leturcq, and Jamel Chelly. Revised spectrum of mutations in sarcoglycanopathies. European Journal of Human Genetics, 16(7):793–803, February 2008. URL: http://dx.doi.org/10.1038/ejhg.2008.9, doi:10.1038/ejhg.2008.9. This article has 66 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/ejhg.2008.9)

[2. (Boulay2015The) Anne-CÃ©cile Boulay, Bruno SaubamÃ©a, Salvatore Cisternino, Virginie Mignon, AurÃ©lien Mazeraud, Laurent Jourdren, Corinne Blugeon, and Martine Cohen-Salmon. The sarcoglycan complex is expressed in the cerebrovascular system and is specifically regulated by astroglial cx30 channels. Frontiers in Cellular Neuroscience, February 2015. URL: http://dx.doi.org/10.3389/fncel.2015.00009, doi:10.3389/fncel.2015.00009. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fncel.2015.00009)

[3. (White2005Sarcoglycanopathies) Stefan J. White, Shirley Uitte de Willige, Dennis Verbove, Luisa Politano, Ieke Ginjaar, Martijn H. Breuning, and Johan T. den Dunnen. Sarcoglycanopathies and the risk of undetected deletion alleles in diagnosis. Human Mutation, 26(1):59–59, 2005. URL: http://dx.doi.org/10.1002/humu.9347, doi:10.1002/humu.9347. This article has 13 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.9347)

[4. (AlonsoPérez2020New) Jorge Alonso-Pérez, Lidia González-Quereda, Luca Bello, Michela Guglieri, Volker Straub, Pia Gallano, Claudio Semplicini, Elena Pegoraro, Vittoria Zangaro, Andrés Nascimento, Carlos Ortez, Giacomo Pietro Comi, Leroy ten Dam, Marianne De Visser, A J van der Kooi, Cristina Garrido, Manuela Santos, Ulrike Schara, Andrea Gangfuß, Nicoline Løkken, Jesper Helbo Storgaard, John Vissing, Benedikt Schoser, Gabriele Dekomien, Bjarne Udd, Johanna Palmio, Adele D’Amico, Luisa Politano, Vincenzo Nigro, Claudio Bruno, Chiara Panicucci, Anna Sarkozy, Omar Abdel-Mannan, Alicia Alonso-Jimenez, Kristl G Claeys, David Gomez-Andrés, Francina Munell, Laura Costa-Comellas, Jana Haberlová, Marie Rohlenová, De Vos Elke, Jan L De Bleecker, Cristina Dominguez-González, Giorgio Tasca, Claudia Weiss, Nicolas Deconinck, Roberto Fernández-Torrón, Adolfo López de Munain, Ana Camacho-Salas, Béla Melegh, Kinga Hadzsiev, Lea Leonardis, Blaz Koritnik, Matteo Garibaldi, Juan Carlos de Leon-Hernández, Edoardo Malfatti, Arturo Fraga-Bau, Isabelle Richard, Isabel Illa, and Jordi Díaz-Manera. New genotype-phenotype correlations in a large european cohort of patients with sarcoglycanopathy. Brain, 143(9):2696–2708, September 2020. URL: http://dx.doi.org/10.1093/brain/awaa228, doi:10.1093/brain/awaa228. This article has 51 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/brain/awaa228)

[5. (Israeli2019An) David Israeli, Jérémie Cosette, Guillaume Corre, Fatima Amor, Jérôme Poupiot, Daniel Stockholm, Marie Montus, Bernard Gjata, and Isabelle Richard. An aav-sgcg dose-response study in a γ-sarcoglycanopathy mouse model in the context of mechanical stress. Molecular Therapy - Methods &amp; Clinical Development, 13:494–502, June 2019. URL: http://dx.doi.org/10.1016/j.omtm.2019.04.007, doi:10.1016/j.omtm.2019.04.007. This article has 24 citations.](https://doi.org/10.1016/j.omtm.2019.04.007)

[6. (Henriques2018Different) Sara F. Henriques, Cécile Patissier, Nathalie Bourg, Chiara Fecchio, Doriana Sandona, Justine Marsolier, and Isabelle Richard. Different outcome of sarcoglycan missense mutation between human and mouse. PLOS ONE, 13(1):e0191274, January 2018. URL: http://dx.doi.org/10.1371/journal.pone.0191274, doi:10.1371/journal.pone.0191274. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0191274)

[7. (Al‐Zaidy2015A) Samiah A. Al‐Zaidy, Vinod Malik, Kelley Kneile, Xiomara Q. Rosales, Ana Maria Gomez, Sarah Lewis, Sayaka Hashimoto, Julie Gastier‐Foster, Peter Kang, Basil Darras, Louis Kunkel, Jose Carlo, Zarife Sahenk, Steven A. Moore, Robert Pyatt, and Jerry R. Mendell. A slowly progressive form of limb‐girdle muscular dystrophy type 2c associated with founder mutation in the sgcg gene in puerto rican hispanics. Molecular Genetics &amp; Genomic Medicine, 3(2):92–98, January 2015. URL: http://dx.doi.org/10.1002/mgg3.125, doi:10.1002/mgg3.125. This article has 10 citations.](https://doi.org/10.1002/mgg3.125)

[8. (Smith2022Novel) Tara C. Smith, Georgios Vasilakos, Scott A. Shaffer, Jason M. Puglise, Chih-Hsuan Chou, Elisabeth R. Barton, and Elizabeth J. Luna. Novel γ-sarcoglycan interactors in murine muscle membranes. Skeletal Muscle, January 2022. URL: http://dx.doi.org/10.1186/s13395-021-00285-2, doi:10.1186/s13395-021-00285-2. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13395-021-00285-2)

[9. (Gao2015Reengineering) Quan Q. Gao, Eugene Wyatt, Jeff A. Goldstein, Peter LoPresti, Lisa M. Castillo, Alec Gazda, Natalie Petrossian, Judy U. Earley, Michele Hadhazy, David Y. Barefield, Alexis R. Demonbreun, Carsten Bönnemann, Matthew Wolf, and Elizabeth M. McNally. Reengineering a transmembrane protein to treat muscular dystrophy using exon skipping. Journal of Clinical Investigation, 125(11):4186–4195, October 2015. URL: http://dx.doi.org/10.1172/jci82768, doi:10.1172/jci82768. This article has 29 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci82768)